United States

Back to map

Showing 101-110 of 328 grants

Title Institution Researcher Program Duration Total Award Amount
In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy Trustees of Columbia University in the City of New York Remi Creusot Cures 01-August-2022 to 31-July-2025 $699,997.82
Development of Low Cost, High Precision Nano Pumps for Insulin Delivery Torramics Inc. Sergey Gimelshein Improving Lives 01-March-2023 to 31-August-2026 $1,493,212.43
GABP regulation of human beta cell proliferation The University of Texas Health Science Center at Houston Richard Cox Cures 01-September-2024 to 31-August-2026 $200,000.00
The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system The University of North Carolina at Chapel Hill Koji Sode Improving Lives 01-October-2022 to 30-September-2025 $799,999.96
Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis The University of Iowa Samuel Stephens Cures 01-June-2024 to 31-May-2027 $750,000.00
Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling The University of Chicago Aly Khan Cures 01-September-2025 to 31-August-2026 $150,000.00
Investigating the role of integrated stress response in type 1 diabetes The University of Chicago Charanya Muralidharan Cures 01-March-2023 to 28-February-2026 $209,066.00
Development of β-Cell Targeted Lipid Nanoparticle Therapeutics The University of Chicago Jacob Ryan Enriquez Cures 01-March-2025 to 29-February-2028 $247,790.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. The University of Chicago Piotr Witkowski Cures 01-September-2025 to 31-August-2029 $8,500,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,000,000.00